Get the Stockscreener App
3.49
2.51%
-0.09
Recursion Pharmaceuticals Inc stock is traded at $3.49, with a volume of 15.96M.
It is down -2.51% in the last 24 hours and down -25.59% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$3.58
Open:
$3.6
24h Volume:
15.96M
Relative Volume:
0.71
Market Cap:
$1.82B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-2.2516
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-12.31%
1M Performance:
-25.59%
6M Performance:
-38.77%
1Y Performance:
-58.94%
1-Day Range:
$3.45
$3.72
1-Week Range:
$3.45
$4.0893
52-Week Range:
$3.45
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.49 | 1.86B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
How rising interest rates impact Recursion Pharmaceuticals Inc. stockTrade Volume Report & Fast Gain Stock Tips - mfd.ru
Recursion Grants New RSUs Raising Questions On Dilution And Dividend Potential - Yahoo Finance
Recursion Pharmaceuticals stock hits 52-week low at $3.53 By Investing.com - Investing.com South Africa
Assessing Recursion Pharmaceuticals (RXRX) After A 58% One-Year Share Price Decline - Yahoo Finance
Is Recursion Pharmaceuticals Inc. stock affected by interest rate hikesJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - mfd.ru
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 12-Month LowTime to Sell? - MarketBeat
Recursion reports grant of inducement awards as permitted by the Nasdaq Listing Rules - marketscreener.com
Recursion Pharmaceuticals stock hits 52-week low at $3.53 - Investing.com
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - marketscreener.com
TechBio firm Recursion grants 820K stock units to 17 new hires - Stock Titan
Baillie Gifford's Strategic Adjustment in Recursion Pharmaceuticals Inc - GuruFocus
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation After New AI Bioengineering Market Study - Sahm
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate - Yahoo Finance
This $4 Stock Could Be Your Ticket to Millionaire Status - The Globe and Mail
Recursion Pharmaceuticals stock hits 52-week low at $3.78 By Investing.com - Investing.com Nigeria
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k - Investing.com
Recursion Pharmaceuticals Stock Jumps on Promising TUPELO Trial Results - StocksToTrade
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $8.66 Million Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Biotech Stocks To Add to Your WatchlistFebruary 5th - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 52-Week LowWhat's Next? - MarketBeat
Boardroom Moves Shake Recursion Pharma Stock - timothysykes.com
Recursion Pharmaceuticals stock hits 52-week low at $3.78 - Investing.com
Recursion Pharmaceuticals (RXRX) Stock Analysis: Biotech Innovator with 67% Potential Upside - DirectorsTalk Interviews
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
Is Recursion Pharmaceuticals Inc. (RXRX) the best overlooked penny stock to invest in? - MSN
Short Squeeze: Is Recursion Pharmaceuticals Inc forming a bullish divergenceJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Setups: Is Recursion Pharmaceuticals Inc forming a bullish divergence2025 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - Yahoo Finance
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift - Newswire Canada
Forget 2025: These 2 Growth Stocks Could Soar in 2026 - AOL.com
Recursion Pharmaceuticals Faces Challenges and Opportunities - Intellectia AI
Can This Beaten-Down AI Stock Bounce Back in 2026? - The Globe and Mail
Can This Beaten-Down AI Stock Bounce Back in 2026? - The Motley Fool
Risk Analysis: Will Canadian Solar Inc benefit from green energy policiesPortfolio Value Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 52.51% Potential Upside in Biotech - DirectorsTalk Interviews
Aug Final Week: Will Recursion Pharmaceuticals Inc benefit from green energy policies2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Will Nvidia-Backed BioHive-2 and Big Pharma Alliances Redefine Recursion Pharmaceuticals' (RXRX) Narrative - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Valuation Check After Analyst Optimism Insider Buying And Nvidia AI Partnership - simplywall.st
Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? - Finviz
Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage? - Sahm
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Feb 03 '26 |
Sale |
4.20 |
220,000 |
924,000 |
6,429,863 |
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):